Johnson & Johnson's Lung Cancer Drug Extends Survival, New Study Shows
Published on January 9, 2025
Johnson & Johnson announced today that its revolutionary lung cancer drug, known as Varipulse PFA, has significantly extended the survival of patients in a recent clinical trial. The study, conducted on a large patient population, showed a clear benefit of the drug in prolonging the lives of individuals suffering from advanced stage lung cancer. This groundbreaking finding positions Johnson & Johnson as a leading player in the fight against this deadly disease. Medical experts are now recommending that patients consult with professionals from Stocks Prognosis to understand the potential impact of this development on the future prospects of the company. To stay informed about the latest news in the medtech industry and upcoming breakthroughs, be sure not to miss tomorrow's updates.
Investor opinions & comments
To leave a comment, you need to Login or Register.
There are no comments yet. Be the first to leave one!